| P2093 | author name string | A J Morgan | |
| P2860 | cites work | Recombinant vaccinia viruses as vaccines | Q70006928 |
| | Establishment and characterization of a chronic infectious mononucleosislike syndrome in common marmosets | Q70140501 |
| | A primate species with limited major histocompatibility complex class I polymorphism | Q33656268 |
| | VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA | Q33971399 |
| | Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals | Q34162117 |
| | DNA sequence and expression of the B95-8 Epstein-Barr virus genome. | Q34245077 |
| | Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes | Q34254100 |
| | Varicella-zoster virus as a live vector for the expression of foreign genes | Q34629086 |
| | Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus | Q34731769 |
| | Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum antibody responses, demonstration of viral DNA, and characterization of viruses | Q36335267 |
| | Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen | Q36390855 |
| | Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity | Q36406027 |
| | Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation | Q36802798 |
| | Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment | Q36806682 |
| | Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells | Q36831966 |
| | Identification of the Epstein-Barr virus gp85 gene | Q36865571 |
| | A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus. | Q36871887 |
| | Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. | Q36873321 |
| | Estimates of the worldwide frequency of twelve major cancers. | Q36875628 |
| | Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells | Q36888549 |
| | Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies | Q36900226 |
| | Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene | Q36901884 |
| | An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200) | Q36911884 |
| | The pathogenesis of Burkitt's lymphoma | Q37888967 |
| | A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340. | Q38354046 |
| | Seroepidemiological studies on nasopharyngeal carcinoma in China. | Q39496258 |
| | Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients. | Q39504173 |
| | Epstein-Barr virus-induced membrane antigens: Immunochemical characterization of triton X-100 solubilized viral membrane antigens from EBV-superinfected raji cells | Q39558367 |
| | Pilot experiments with eb virus in owl monkeys(aotus trivirgatus). III. Serological and biochemical findings in an animal with reticuloproliferative disease | Q39928131 |
| | Epstein-Barr Virus — Is It Time To Develop a Vaccine Program? | Q39980322 |
| | Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity | Q40059138 |
| | Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones | Q40067251 |
| | Passive immunity to bovine rotavirus infection associated with transfer of serum antibody into the intestinal lumen | Q40128515 |
| | Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). | Q41211049 |
| | Transcription and DNA sequence of the BamHI L fragment of B95-8 Epstein-Barr virus. | Q41571316 |
| | Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis | Q42074715 |
| | High incidence of Epstein-Barr virus genomes in Hodgkin's disease. | Q42773829 |
| | Radioimmune precipitation study comparing the epstein-barr virus membrane antigens expressed on P3HR-1 virus-superinfected Raji cells to those expressed on cells in a B-95 virus-transformed producer culture activated with tumor-promoting agent (TPA) | Q43971890 |
| | Characterization of N- and O-linked oligosaccharides of glycoprotein 350 from Epstein-Barr virus | Q44108266 |
| | Purification and Properties of the gp340 Component of Epstein--Barr Virus Membrane Antigen in an Immunogenic Form | Q44130250 |
| | Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens-induced by the virus. | Q44269249 |
| | Are continuous cell lines safe as substrates for human drugs and biologics? A case study with human growth hormone | Q44480046 |
| | Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones | Q44528938 |
| | Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease | Q44983123 |
| | Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. | Q45735984 |
| | Comparative immunogenicity studies on epstein-barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins | Q45796523 |
| | Replication of Epstein–Barr virus in human epithelial cells infected in vitro | Q45797458 |
| | Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects | Q45799485 |
| | Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation | Q45800684 |
| | Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides | Q45805691 |
| | Infectious mononucleosis-like response in common marmosets infected with Epstein-Barr virus | Q45807200 |
| | Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus | Q45834521 |
| | Epstein-Barr virus infections in males with the X-linked lymphoproliferative syndrome | Q45835183 |
| | Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine | Q45837672 |
| | In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340. | Q45839679 |
| | Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine | Q45840919 |
| | Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes | Q45841202 |
| | Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas | Q45841336 |
| | Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography | Q45841790 |
| | Epstein-Barr virus associated B-cell lymphomas in AIDS and after organ transplantation | Q45844628 |
| | Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. | Q45845005 |
| | Vero cell-expressed Epstein-Barr virus (EBV) gp350/220 protects marmosets from EBV challenge | Q45846316 |
| | Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220. | Q45848116 |
| | Improvement of hepatitis B vaccine by the use of a new adjuvant | Q46587331 |
| | Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti-MA). | Q53598601 |
| | Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx | Q56689988 |
| | Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA regions | Q59070031 |
| | Vaccination of non-human primates against malignant lymphoma | Q67506789 |
| | Alterations of the immunological specificity of plasma membranes from cells infected with Marek's disease and turkey herpes viruses | Q68353111 |
| | Truncated versions of the two major Epstein-Barr viral glycoproteins (gp250/350) are secreted by recombinant Chinese hamster ovary cells | Q69814256 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| P304 | page(s) | 249-262 | |
| P577 | publication date | 1991-01-01 | |
| P1433 | published in | Seminars in Immunopathology | Q15724576 |
| P1476 | title | Control of viral disease: the development of Epstein-Barr virus vaccines | |
| P478 | volume | 13 | |